Xcout IntelAntiva Biosciences, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Antiva Biosciences, Inc. among biotechnology companies — ranked by similarity to what Antiva Biosciences, Inc. actually does, not by market-cap band.
Subscribe to see Antiva Biosciences, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Antiva Biosciences, Inc.
Antiva Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm focuses on biotechnology research and developing treatments for viral infections and precancerous conditions.
Antiva Biosciences, Inc. at a glance
Antiva Biosciences, Inc. is a biotechnology company headquartered in United States. Its most recent funding round raised $38.5M in April 2023. Xcout tracks 7 named people at Antiva Biosciences, Inc., including Kristine Ball (President & CEO, Antiva Biosciences).
Antiva Biosciences, Inc. leadership
- Kristine BallPresident & CEO, Antiva Biosciences
- Gail MaderisChairman
- Beni RovinskiManaging Director, Lumira Ventures
- Wende S. HuttonDirector
- Clifford M. SamuelPrincipal, PCMS1 Consulting
- David MoskowitzPrincipal, MPM Bioimpact
1 more named person on record for Antiva Biosciences, Inc., with roles, board committees and tenure — see the full roster →
Antiva Biosciences, Inc. funding rounds
The 6 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $38.5M | — | |
| Series E | $53M | 6 named | |
| SEC Form D filing | $15.6M | — | |
| Series C-1 | $15M | 8 named | |
| SEC Form D filing | $14.7M | — | |
| Series C | $22M | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Antiva Biosciences, Inc. competitors
Ranked by semantic similarity — how close each company is to Antiva Biosciences, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Centivax is a privately held, clinical-stage biotechnology company headquartered in South San Francisco, California. The company focuses on accelerating the transition to a post-pathogen world by developing broad-spectrum vaccines, COVID-19 therapeutics, and antivenom antibodies.
Similar biotechnology company
Excision BioTherapeutics Inc. is a San Francisco-based clinical-stage biotechnology company focused on developing advanced gene editing therapeutics to treat infectious diseases.
Similar biotechnology company
Adynxx, Inc. is a clinical-stage biopharmaceutical company headquartered in San Francisco, California, focused on biotechnology research and drug development.
Similar biotechnology company
Red Queen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on antiviral therapeutics, with its headquarters located in Cambridge, Massachusetts.
Similar biotechnology company
Antios Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Mendham, New Jersey, focused on developing innovative therapies to treat and cure chronic hepatitis B virus.
Biotech
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
Biotech
Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Carlsbad, California. The company focuses on the development of novel oral antiviral treatments for viral diseases.
Biotech
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
Similar biotechnology company
Khloris Biosciences, Inc. is a life sciences company focused on therapeutic development with locations in California, including San Jose and South San Francisco.
Similar biotechnology company
Amphivena Therapeutics, Inc. is a privately held, clinical-stage biotechnology company based in South San Francisco, California. The company specializes in immuno-oncology, developing a platform of dual-function biologics and selective T cell engagers for the treatment of hematological conditions.
Biotech
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic malignancies and solid tumors. This includes ATA2271 and ATA3271 targeting mesothelin, alongside ATA2431 and ATA3219 for B-cell malignancies. Furthermore, Atara is developing ATA188 for the treatment of multiple sclerosis and the ATA368 program specifically for cancers associated with human papillomavirus (HPV). To bolster its research and development efforts, Atara Biotherapeutics has established significant collaborations and licensing agreements. These include a licensing partnership with Memorial Sloan Kettering Cancer Center, a license and R&D collaboration with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Additionally, the company holds a strategic partnership with Bayer AG focused on mesothelin-targeted CAR T-cell therapies for solid tumors.
Biotech
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Antiva Biosciences, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Antiva Biosciences, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →